Desvenlafaxine in the treatment of major depression: an updated overview
Expert Opin Pharmacother. 2021 Mar 11. doi: 10.1080/14656566.2021.1900826. Online ahead of print.ABSTRACTIntroduction: Major depressive disorder (MDD) remains one of the most prevalent mental health conditions. It is a chronic, relapsing condition and despite multiple treatment options, many patients fail to achieve remission of symptoms. Inadequacy of treatment has stimulated the search for agents with significant therapeutic advantages.Areas covered: This review examines literature concerning the use of desvenlafaxine in the treatment of MDD published since a previous analysis in this journal in 2014. Published papers we...
Source: Expert Opinion on Pharmacotherapy - March 12, 2021 Category: Drugs & Pharmacology Authors: Trevor R Norman James S Olver Source Type: research
Venlafaxine and desvenlafaxine to be included in the surface water Watch List
Aust N Z J Psychiatry. 2021 Feb 26:4867421998787. doi: 10.1177/0004867421998787. Online ahead of print.NO ABSTRACTPMID:33636994 | DOI:10.1177/0004867421998787 (Source: The Australian and New Zealand Journal of Psychiatry)
Source: The Australian and New Zealand Journal of Psychiatry - February 27, 2021 Category: Psychiatry Authors: Unax Lertxundi Saioa Domingo-Echaburu Rafael Hernandez Juan Medrano Gorka Orive Source Type: research
Venlafaxine and desvenlafaxine to be included in the surface water Watch List
Aust N Z J Psychiatry. 2021 Feb 26:4867421998787. doi: 10.1177/0004867421998787. Online ahead of print.NO ABSTRACTPMID:33636994 | DOI:10.1177/0004867421998787 (Source: The Australian and New Zealand Journal of Psychiatry)
Source: The Australian and New Zealand Journal of Psychiatry - February 27, 2021 Category: Psychiatry Authors: Unax Lertxundi Saioa Domingo-Echaburu Rafael Hernandez Juan Medrano Gorka Orive Source Type: research
Venlafaxine and desvenlafaxine to be included in the surface water Watch List
Aust N Z J Psychiatry. 2021 Feb 26:4867421998787. doi: 10.1177/0004867421998787. Online ahead of print.NO ABSTRACTPMID:33636994 | DOI:10.1177/0004867421998787 (Source: The Australian and New Zealand Journal of Psychiatry)
Source: The Australian and New Zealand Journal of Psychiatry - February 27, 2021 Category: Psychiatry Authors: Unax Lertxundi Saioa Domingo-Echaburu Rafael Hernandez Juan Medrano Gorka Orive Source Type: research
Depression in Alzheimer's Disease: A Delphi Consensus on Etiology, Risk Factors, and Clinical Management
Conclusions: This study sheds light on several unresolved clinical challenges regarding depression in dementia patients. Further studies and specific recommendations for this comorbid patient population are still needed. (Source: Frontiers in Psychiatry)
Source: Frontiers in Psychiatry - February 26, 2021 Category: Psychiatry Source Type: research
Focus on Depression in Parkinson's Disease: A Delphi Consensus of Experts in Psychiatry, Neurology, and Geriatrics
Parkinsons Dis. 2021 Feb 8;2021:6621991. doi: 10.1155/2021/6621991. eCollection 2021.ABSTRACTMajor and minor forms of depression are significant contributors to Parkinson's disease morbidity and caregiver burden, affecting up to 50% of these patients. Nonetheless, symptoms of depression are still underrecognized and undertreated in this context due to scarcity of evidence and, consequently, consistent clinical guideline recommendations. Here, we carried out a prospective, multicentre, 2-round modified Delphi survey with 49 questions about the aetiopathological mechanisms of depression in Parkinson's disease (10), clinical ...
Source: Parkinsons Disease - February 25, 2021 Category: Neurology Authors: Luis Ag üera-Ortiz Roc ío García-Ramos Francisco J Grandas P érez Jorge L ópez-Álvarez Jos é Manuel Montes Rodríguez F Javier Olazar án Rodríguez Javier Olivera Pueyo Carmelo Pelegr ín Valero Jes ús Porta-Etessam Source Type: research
